Clinical trials: Early-Stage Cancer
Early Lumbar Disc Degeneration
A Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal rhGDF-5 for the Treatment of Early Stage Lumbar Disc Degeneration
Study to show the safety, tolerability and preliminary effectiveness of Intradiscal rhGDF-5 in subjects with early lumbar disc degeneration.
- Trial name
- NCT01158924
- Testing
- Intradiscal rhGDF-5
- Where
- 3 sites in Australia
- Volunteers
- 40 people
- Sponsor
- DePuy Spine
Breast Cancer
Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery
RATIONALE: It is not yet know whether higher per daily radiation therapy is equally as effective as standard per daily radiation therapy in treating breast cancer.
- Trial name
- NCT01349322
- Testing
- Standard fractionation whole breast irradiation, Hypofractionated whole breast irradiation, Concurrent boost
- Where
- 415 sites in United States, Canada and 6 more
- Volunteers
- 2,354 people
- Sponsor
- Radiation Therapy Oncology Group
Metastatic Breast Cancer
Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression
This is a multicenter, open-label, single-arm Phase II study designed to evaluate the effect of T-DM1 on the duration of corrected QT (QTc) interval in patients with HER2-positive locally advanced or metastatic breast cancer and…
- Trial name
- NCT00943670
- Testing
- pertuzumab, Trastuzumab emtansine [Kadcyla]
- Volunteers
- 51 people
- Sponsor
- Genentech, Inc.
Non-small Cell Lung Cancer
Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)
In this study, participants with Stage IB/II-IIIA non-small cell lung cancer (NSCLC) who have undergone surgical resection (lobectomy or pneumonectomy) with or without adjuvant chemotherapy will be treated with pembrolizumab or…
- Trial name
- PEARLS (NCT02504372)
- Testing
- Pembrolizumab
- Volunteers
- 1,177 people
- Sponsor
- Merck Sharp & Dohme LLC
Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer
This randomized phase III trial studies pelvic radiation therapy to see how well it works compared with vaginal implant radiation therapy, paclitaxel, and carboplatin in treating patients with high-risk stage I or stage II…
- Conditions
- Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Fatigue, Neurotoxicity Syndrome
- Trial name
- NCT00807768
- Testing
- 3-Dimensional Conformal Radiation Therapy, Carboplatin, Intensity-Modulated Radiation Therapy
- Where
- 540 sites in United States, South Korea
- Volunteers
- 601 people
- Sponsor
- Gynecologic Oncology Group
Non-small Cell Lung Cancer
Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
In this research study erlotinib will be given to eligible participants whose lung cancer has been removed by surgery. Eligible patients have adenocarcinoma, a type of non-small lung cancer, and must have 1 or more of the…
- Trial name
- NCT00567359
- Testing
- Erlotinib
- Where
- 8 sites in United States
- Volunteers
- 100 people
- Sponsor
- Massachusetts General Hospital
Relief of Joint Pain
Vitamin B12 for Aromatase Inhibitors Musculoskeletal Symptoms
Significant Aromatase Inhibitor-associated toxicity, affects as many as 50% of patients with breast cancer leading to early discontinuation of this life-saving cancer treatment.
- Trial name
- NCT03069313
- Testing
- Vitamin B12
- Volunteers
- 41 people
- Sponsor
- Texas Tech University Health Sciences Center, El Paso
Extensive Stage Lung Small Cell Carcinoma, Extrapulmonary Small Cell Neuroendocrine Carcinoma
Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs
This phase II trial studies how well berzosertib (M6620) works when given in combination with topotecan hydrochloride (topotecan) compared with topotecan alone in treating patients with small cell lung cancer that has come back…
- Conditions
- Extensive Stage Lung Small Cell Carcinoma, Extrapulmonary Small Cell Neuroendocrine Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma
- Trial name
- NCT03896503
- Testing
- Berzosertib, Biopsy Procedure, Biospecimen Collection
- Where
- 33 sites in United States
- Volunteers
- 104 people
- Sponsor
- National Cancer Institute (NCI)
Myeloproliferative Disorders, Kidney Cancer
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00787761
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Northside Hospital, Inc.
Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma
Pioglitazone Hydrochloride in Treating Patients With Stage IA-IIIA Non-small Cell Lung Cancer
This pilot phase II trial studies how well pioglitazone works in treating patients with stage IA-IIIA non-small cell lung cancer.
- Conditions
- Stage IA Non-Small Cell Lung Carcinoma, Stage IB Non-Small Cell Lung Carcinoma, Stage IIA Non-Small Cell Lung Carcinoma, Stage IIB Non-Small Cell Lung Carcinoma
- Trial name
- NCT01342770
- Testing
- Laboratory Biomarker Analysis, Pioglitazone Hydrochloride, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer Stage II
Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer
Anlotinib is an oral multi-targeted tyrosine kinase inhibitor (TKI) that strongly inhibits VEGFR, PDGFR, FGFR, and c-kit. Combining anti-angiogenesis with chemotherapy yielded increased response rates in patients with early-stage…
- Trial name
- ACNTBC (NCT05558722)
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Xijing Hospital
Nonmelanoma Skin Cancer
Comparison of eBX and Mohs Surgery for Treatment of Early-stage Non-melanoma Skin Cancer a Matched Pair Cohort Study.
This is a retrospective-prospective study design. Patients who completed treatment approximately 3 years (range of 2-4 years) at time of IRB approval of this study will be identified and any existing data in the patient's record…
- Trial name
- NCT03024866
- Testing
- Electronic Brachytherapy
- Where
- 4 sites in United States
- Volunteers
- 369 people
- Sponsor
- Xoft, Inc.
Early Stage Non-Small Cell Lung Cancer
SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)
The purpose of the study is to determine whether avelumab has an effect on cancer and body in combination with SBRT, a standard treatment for early stage non-small cell lung cancer (NSCLC).
- Trial name
- NCT03050554
- Testing
- Avelumab, SBRT
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Andrew Sharabi
Breast Cancer
Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer
The purpose of this study is to find out what effects the preoperative combination therapies of herceptin/navelbine or herceptin/taxotere/carboplatin will have on patients with early stage HER-2 positive breast cancer.
- Trial name
- NCT00148668
- Testing
- Herceptin, Navelbine, Taxotere
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- Eric Winer, MD
Hepatocellular Carcinoma, Hepatoma
TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma
This is a single-center, prospective RCT to study the effectiveness of TACE and MWA combination therapy with MWA monotherapy for the treatment of early HCC. Primary outcome is 2-year intrahepatic disease-free survival.
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult, Liver Cell Carcinoma
- Trial name
- NCT02704130
- Testing
- Transarterial embolization, Microwave Ablation
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Wake Forest University Health Sciences
Lung Cancer
Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
RATIONALE: Diagnostic procedures, such as positron emission tomography (PET), (done before, during, and after chemotherapy) may help doctors predict a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT00227539
- Testing
- cisplatin, pemetrexed disodium, adjuvant therapy
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Washington
Breast Cancer
A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer
This multicenter, non-randomized, open-label, phase 2 study is designed to evaluate the safety and efficacy of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and anthracycline-based chemotherapy as neoadjuvant…
- Trial name
- BERENICE (NCT02132949)
- Testing
- 5-Fluorouracil, Cyclophosphamide, Docetaxel
- Where
- 80 sites in United States, Canada and 10 more
- Volunteers
- 401 people
- Sponsor
- Hoffmann-La Roche
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
This phase I/II trial studies the side effects and best dose of donor natural killer (NK) cell therapy and to see how well it works when given together with fludarabine phosphate, cyclophosphamide, total-body irradiation, donor…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma
- Trial name
- NCT00789776
- Testing
- Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Fred Hutchinson Cancer Center
Small Cell Lung Cancer
Chemotherapy and Radiotherapy to Treat Patients With Limited Stage of Small Cell Lung Cancer (SCLC)
This is a multicenter, phase II, open-label trial to evaluate the efficacy of pemetrexed + carboplatin combined with thoracic radiotherapy in patients with Limited Stage of small cell lung cancer
- Trial name
- NCT00494026
- Testing
- pemetrexed, carboplatin, radiotherapy
- Where
- 12 sites in Italy, Poland and 2 more
- Volunteers
- 4 people
- Sponsor
- Eli Lilly and Company
Lyme Disease
Detection of Borrelia Bacteria in Early Stage Lyme Borreliosis Using the T2Lyme Panel
The T2Lyme assay will be compared to Borrelia culture from erythema migrans (EM) biopsy and/or detection of the C6 antigen in serum collected prospectively from patients suspected of early Lyme disease.
- Trial name
- NCT03581279
- Testing
- T2Lyme Panel testing
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- T2 Biosystems